Views on Ranbaxy Labs 5QFY2014 results - Angel Broking

Views of Ms. Sarabjit Kour Nangra (VP Research-Pharma, Angel Broking) on Ranbaxy Labs 5QFY2014 results:

"Ranbaxy, posted numbers below the expectations. For the quarter, the company posted sales of Rs. 2436cr V/s Rs. 2,657cr expected, posting a dip of 0.2% ( Rs. 2440cr in 1QCY2013). While, the quarterly sales were lower than expected the company met its annual guidance of sales of Rs. 13,000cr for FY2014. Its key market USA , grew by almost 13% yoy during the quarter. On, the operating front, the OPM's came in at 4.9% V/s 6.4% expected and 4.0% in 1QCY2013. Apart from, the OPM, the other income dipped by 55.8% yoy, along with the higher taxation lead the company post a net loss before exceptions at Rs. 93cr V/s Rs. 46cr profit during the last corresponding period. This was much lower than expected net profit of Rs. 240cr during the period. The reported net loss of the company was around Rs. 74cr V/s net profit of Rs. 125cr during the period. We remain neutral on the stock."

Ranbaxy labs (CMP:Rs. 469 / TP:- / Upside:-)

Source : Equity Bulls

Keywords